CRISPR-Cas Systems in Bacteria: Discovery and Applications- Rodolphe Barrangou & Philippe Horvath
CRISPR-Cas Systems in Bacteria: Discovery and Applications- Rodolphe Barrangou & Philippe Horvath
2016 Canada Gairdner International Awardees present the work that won the prize at the Annual Awardees Symposium in Toronto, Canada.
Rodolphe Barrangou, Ph.D., Associate Professor, Department of Food, Bioprocessing and Nutrition Sciences; Todd R. Klaenhammer Distinguished Scholar in Probiotics Research North Carolina State University, Raleigh, North Carolina, USA , and Philippe Horvath, Ph.D., Senior Scientist, DuPont Fellow Forum Associate, DuPont Nutrition and Health, Dangé-Saint-Romain, France
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.